文献速递核素与放射性配体治疗肿瘤 PET/CT

前列腺癌患者的眼部症状

Eye Symptoms in a Patient With Prostate Cancer.
PubMed 文献 · Clin Nucl Med · 2020-01-01

一名66岁去势抵抗性前列腺癌患者接受F-PSMA 1007 PET/CT显示颅骨、胸部、脊柱、骨盆和四肢广泛PSMA阳性骨转移,随后接受Lu-PSMA-617治疗。24小时SPECT/CT显示左眼附近额外活性,第一周期后因疼痛行活检,第二治疗周期后该活性在SPECT/CT上不可见,眼痛缓解。

要点

  • 去势抵抗性前列腺癌患者F-PSMA 1007 PET/CT显示颅骨、胸部、脊柱、骨盆和四肢广泛PSMA阳性骨转移。
  • Lu-PSMA-617治疗后24小时SPECT/CT显示左眼附近额外活性,F-PSMA未见。
  • 第一周期后因疼痛行活检,第二治疗周期后SPECT/CT上该活性不可见,眼痛缓解。

核心结论

  • Lu-PSMA-617治疗后24小时SPECT/CT显示左眼附近额外活性,第二治疗周期后该活性不可见且眼痛缓解。

研究设计与样本

  • 66岁去势抵抗性前列腺癌患者,接受F-PSMA 1007 PET/CT和Lu-PSMA-617治疗,第一周期后因疼痛行活检。

主要发现

  • F-PSMA 1007 PET/CT显示颅骨、胸部、脊柱、骨盆和四肢广泛PSMA阳性骨转移。
  • Lu-PSMA-617治疗后24小时SPECT/CT显示左眼附近额外活性,F-PSMA未见。
  • 第一周期后因疼痛行活检,第二治疗周期后SPECT/CT上该活性不可见,眼痛缓解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 66-year-old man with castration-resistant prostate cancer was evaluated with F-prostate-specific membrane antigen (PSMA) 1007 PET/CT, which revealed extensive PSMA-positive skeletal metastases in the skull, thorax, spine, pelvis, and extremities. He was then treated Lu-PSMA-617 therapy. Twenty-four-hour SPECT/CT revealed additional activity not seen with F-PSMA adjacent to his left eye. The lesion was biopsied after the first cycle due to pain. This activity was not visible on SPECT/CT after the second treatment cycle, and his eye pain has resolved.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kairemo K, Kangasmäki A, Joensuu T, et al. Eye Symptoms in a Patient With Prostate Cancer. Clin Nucl Med. 2020. PMID: 32149800. doi:10.1097/RLU.0000000000002982

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。